Tango Therapeutics Q2 net loss widens to $55.3 million; G&A expenses climb 99% to $22.6 million

Tango said vopimetostat with daraxonrasib showed a 92% objective response rate in MTAP-deleted RAS-mutant pancreatic cancer.

The company is targeting Phase 3 design finalization in the second half of 2026.

Cash, cash equivalents and marketable securities totaled $1.0 billion at June 30, 2026.

Collaboration revenue was no revenue, compared with $3.2 million a year earlier.

Tango Therapeutics posted a second-quarter net loss of $55.3 million, widening from $38.9 million a year earlier. Loss per share was $0.37.

Research and development expenses rose to $37.2 million from $32.8 million, driven by higher spending on the and programs.